Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for October

02 Nov 2026, 12:41 by Scott Moore · The Cerbat Gem

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 15,751 shares, a decrease of 38.8% from the September 30th total of 25,736 shares. Based on an average daily volume of 26,150 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.50.

Check Out Our Latest Stock Report on Bolt Biotherapeutics

Bolt Biotherapeutics Price Performance

NASDAQ BOLT traded down $0.23 during trading on Monday, hitting $6.36. 6,747 shares of the stock traded hands, compared to its average volume of 91,919. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. Bolt Biotherapeutics has a 12-month low of $3.10 and a 12-month high of $7.78. The firm has a 50-day simple moving average of $4.14 and a 200-day simple moving average of $4.52. The company has a market capitalization of $12.28 million, a P/E ratio of -0.39 and a beta of 0.84.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, analysts predict that Bolt Biotherapeutics will post -11.10 EPS for the current year.

Insider Transactions at Bolt Biotherapeutics

In other news, CEO William Quinn sold 9,132 shares of Bolt Biotherapeutics stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the sale, the chief executive officer owned 25,384 shares in the company, valued at $82,244.16. This trade represents a 26.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 38,584 shares of company stock worth $128,361. Company insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Bolt Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) by 40.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,225 shares of the company’s stock after acquiring an additional 22,200 shares during the quarter. Renaissance Technologies LLC owned about 4.02% of Bolt Biotherapeutics worth $312,000 as of its most recent SEC filing. 86.70% of the stock is currently owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.